Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9593180 | 0.87 | IMPDH2 (0.50) | IMPDH2IMPDH1ATMAPPGPR84 | |
| SCHEMBL8998932 | 0.83 | IMPDH2 (0.46) | IMPDH2IMPDH1ATMAPPGPR84 | |
| SCHEMBL8999076 | 0.83 | IMPDH2 (0.46) | IMPDH2IMPDH1ATMAPPGPR84 | |
| SCHEMBL11797189 | 0.81 | ATM (0.50) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL799601 | 0.80 | ATM (0.54) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL1685393 | 0.80 | ATM (0.54) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL13335152 | 0.80 | ATM (0.54) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL30437029 | 0.80 | ATM (0.54) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL29885789 | 0.80 | ATM (0.54) | IMPDH2IMPDH1ATMGPR84MEN1 | |
| SCHEMBL20110126 | 0.77 | HTR2A (0.44) | MEN1KMT2AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104529865-B | Benzylamine derivatives and application thereof in medicines | 广东东阳光药业有限公司 | 2017-02-01 | — | — | CN | disclosed |
| CN-104496987-B | Compound substitution heterocycle class and the application on medicine thereof | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-03-02 | — | — | CN | disclosed |
| CN-104529866-A | Indole derivatives and application thereof in medicines | GUANGDONG HEC PHARMACEUTICAL | 2015-04-22 | — | — | CN | disclosed |
| CN-104529865-A | Benzylamine derivatives and application thereof in medicines | GUANGDONG HEC PHARMACEUTICAL | 2015-04-22 | — | — | CN | disclosed |
| CN-104496987-A | Substituted heterocyclic compound and application thereof in medicines | GUANGDONG HEC PHARMACEUTICAL | 2015-04-08 | — | — | CN | disclosed |
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| EP-1539141-B1 | 3-(SULFONAMIDOETHYL)-INDOLE DERIVATIVES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007002637-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| CN-1678306-A | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases | BOEHRINGER INGELHEIM PHARMA (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | IMPDH2 1828/4885IMPDH1 1473/4885ATM 4001/4885 |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | IMPDH2 4655/4885IMPDH1 4117/4885ATM 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.